PsychedelicNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Appoints Members to Newly Formed Medical Advisory Board

August 26, 2021 09:06:59

Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has created a Medical Advisory Board to advise the company and its subsidiaries in developing safety protocols and best practices. Board members include an impressive array of medical professionals including a neuroscientist, anesthesiologist, addiction psychiatrist, interventional pain physician and more. These board members were carefully appointed to serve as thought leaders and advisors. The board will serve as an invaluable resource for Delic as it focuses on developing psychedelic wellness treatments today as well as looking toward the future. In addition, board members will be a resource for media, other medical associates and general audiences interested in the science behind psychedelic wellness and treatments. Initial board members include Dr Matthew Cook, MD, president and founder of BioReset(TM) Medical and a medical advisor to BioReset Network; Dr. David Rabin, MD, PhD, a board certified psychiatrist and neuroscientist as well as co-founder and chief innovation officer of Apollo Neuroscience and co-founder and executive director of The Board of Medicine; Dr. Iru Gerard Fernando, MD,a board certified general and addiction psychiatrist as well as the medical director of addiction services at Psychiatric Wellness Center and division medical director for Aspire Behavioral Health; Dr. Chris Ray, PhD, and interventional pain physician; Yessica Avancena, MFT, MBA, a certified mindfulness teacher (“CMT”), psychotherapist and entrepreneur; and Barbara Branaman, the co-founder and CEO of the suite of BioReset brands, products and services, including BioReset University. “Science and medicine are the basis of Delic’s approach to psychedelic wellness and our experienced and diverse Medical Advisory Board will help ensure our commitment to safety, quality and efficacy of treatments,” said Delic CEO Matt Stang in the press release. “This impressive group represents well-known leaders in the psychedelic and addiction fields and will help usher in a greater understanding of the science and data behind what we expect to be the most effective treatments for many mental health conditions ever available.”

To view the full press release, visit

About Delic Corp Inc.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms such as Reality Sandwich; Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic,  the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network whose mission is to provide education, research, high-quality products and treatment options to the masses. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.